Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $10.7650 (2.04%) ($10.7650 - $10.7650) on Wed. Nov. 29, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.37% (three month average) | RSI | 43 | Latest Price | $10.7650(2.04%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | FOLD advances 0.3% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) XBI(70%) IBB(69%) SPY(69%) QQQ(67%) TAN(67%) | Factors Impacting FOLD price | FOLD will decline at least -1.685% in a week (0% probabilities). EDOC(-77%) UUP(-12%) VIXM(-10%) TBT(-9%) XLE(-5%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.685% (StdDev 3.37%) | Hourly BBV | 1.1 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $3.05(-71.67%) | Resistance Level | $10.81 | 5 Day Moving Average | $10.63(1.27%) | 10 Day Moving Average | $10.7(0.61%) | 20 Day Moving Average | $10.81(-0.42%) | To recent high | -19.3% | To recent low | 8% | Market Cap | $2.78b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |